Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.11500.0000 (0.00%)
At close: 03:38PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1150
Open0.1000
Bid0.0900 x N/A
Ask0.1150 x N/A
Day's Range0.0900 - 0.1150
52 Week Range0.0900 - 0.3900
Volume12,500
Avg. Volume10,541
Market Cap3.747M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Marvel Biosciences Initiates Formulation Development with Catalent

    Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent, Inc.Catalent, one of the world's largest contract research organizations, has begun development of novel solid ...

  • Newsfile

    Marvel Biosciences Announces Second Quarter 2022 Financial Results

    Calgary, Alberta--(Newsfile Corp. - March 30, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") today announced its financial results for the second quarter ended January 31, 2022. For further information on these results, please see the Marvel Biosciences Corp. Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis as filed on SEDAR."During the quarter ended January

  • Newsfile

    Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results

    Calgary, Alberta--(Newsfile Corp. - February 16, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report the proxy tabulation ("Tabulation") from Odyssey Trust Company in connection with its Annual and Special Meeting of Shareholders held virtually on February 15, 2022 (the "Meeting"), as well as results from the Meeting.The Tabulation is the final sum of the voting results of the Meet

Advertisement
Advertisement